Evidence map›Paper›PMID 32920865›Full record

ArticleGenes, chromosomes & cancer2021

Poorly differentiated chordoma with whole-genome doubling evolving from a SMARCB1-deficient conventional chordoma: A case report.

Christian Curcio, Robert Cimera, Ruth Aryeequaye, Mamta Rao, Nicola Fabbri, Yanming Zhang, Meera Hameed

Open access · greenAbstract readCase Reports
In one paragraph

Article in Genes, chromosomes & cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Translational Aspects of Epithelioid Sarcoma: Current Consensus.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Christian CurcioDepartment of Pathology and Laboratory Medicine, Hospital for Special Surgery, New York, New York, USA.ORCID 0000-0003-4742-0347
Robert CimeraDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Ruth AryeequayeDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Mamta RaoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Nicola FabbriDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Yanming ZhangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Meera HameedDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Memorial Sloan Kettering Cancer Center · USHospital for Special Surgery · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Evolution of poorly differentiated chordoma from conventional chordoma has not been previously reported. We encountered a case of a poorly differentiated chordoma with evidence of whole-genome doubling arising from a SMARCB1-deficient conventional chordoma. The tumor presented as a destructive sacral mass in a 43-year-old man and was comprised of a highly cellular poorly differentiated chordoma with small, morphologically distinct nodules of conventional chordoma accounting for <5% of the total tumor volume. Immunohistochemistry (IHC) revealed both components were strongly reactive for brachyury and lacked normal staining for INI1. Single nucleotide polymorphism (SNP) array analysis identified multiple genomic imbalances in the conventional component, including deletions of 1p, 3p, and 22q (involving SMARCB1) and loss of chromosomes 5 and 15, while the poorly differentiated component exhibited the same aberrations at a more profound level with additional loss of chromosome 4, low level focal deletion of 17p (involving TP53), and tetraploidy. Homozygous deletion of SMARCB1 was present in both components. Fluorescence in situ hybridization (FISH) analysis confirmed the relevant deletions in both components as well as genome doubling in the poorly differentiated tumor. This case suggests that SMARCB1 loss is an early event in rare conventional chordomas that could potentially evolve into poorly differentiated chordoma through additional genomic aberrations such as genome doubling. Further studies with additional patients will be needed to determine if genome doubling is a consistent pathway for evolution of poorly differentiated chordoma.

Indexed as

Chromosome DeletionTetraploidyAdultBrachyury ProteinChordomaFetal ProteinsHumansMaleSacrumSMARCB1 ProteinSpinal NeoplasmsT-Box Domain ProteinsBrachyury ProteinFetal ProteinsSMARCB1 ProteinSMARCB1 protein, humanT-Box Domain Proteinsconventional chordomapoorly differentiated chordomaSMARCB1whole-genome doubling

Identifiers

PMID32920865
PMCPMC7755306
OpenAlexW3084892162

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.